Moreover, the low-risk group had high tumor purity, high FPI, more mutations, more enrichment of immune-related pathways, more CD4+ T-related cells, higher expression of immune checkpoints, and easy response to immune checkpoint inhibitor immunotherapy. The gene discussed is CD4; the disease is neoplasm.